Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro

Oncogene

Volumn 32, Issue 48, 2013, Pages 5449-5457

  Ki, M K ^a   Jeoung, M H ^a   Choi, J R ^a   Rho, S S ^b   Kwon, Y G ^b   Shim, H ^c   Chung, J ^d   Hong, H J ^e   Song, B D ^a   Lee, S ^a  

^a Scripps Korea Antibody Institute   (South Korea)

^b Yonsei University   (South Korea)

^c Ewha Womans University   (South Korea)

^d Seoul National University   (South Korea)

^e Kangwon National University   (South Korea)

Author keywords

Angiogenesis; Antibody; C type lectin like domain; Clec14a; Endothelial cell; Regulation

Indexed keywords

CELL PROTEIN; IMMUNOGLOBULIN G; PROTEIN CLEC14A; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL CONTACT; CELL MIGRATION; CONTROLLED STUDY; CROSS LINKING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODY SPECIFICITY; CELL ADHESION MOLECULES; CELL COMMUNICATION; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN G; LECTINS, C-TYPE; MEMBRANE PROTEINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; PSEUDOPODIA; SINGLE-CHAIN ANTIBODIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84889083761     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.156     Document Type: Article

References (29)

1. Teillaud JL. From whole monoclonal antibodies to single domain antibodies: Think small. Methods Mol Biol 2012; 911: 3-13
2. Zilian O. Scope for innovation in immunotherapy from the financial market's point of view: Phacilitate Immunotherapy Leaders' Forum 2012. Hum Vaccin Immunother 2012; 8: 1370-1372
3. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012; 2: A006502
4. Tortora G, Melisi D, Ciardiello F. Angiogenesis: A target for cancer therapy. Curr Pharm Des 2004; 10: 11-26
5. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004; 9(Suppl 1): 36-42
6. Dienstmann R, Markman B, Tabernero J. Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol 2012; 7: 137-145
7. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530
8. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ et al. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-265
9. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 2008; 68: 93-106
10. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002; 1: 507-514
11. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28: 453-459
12. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589-4599
13. Rho SS, Choi HJ, Min JK, Lee HW, Park H, Kim YM et al. Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun 2011; 404: 103-108
14. Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 2012; 31: 293-305
15. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350: 2335-2342
17. Gordon MS, Margolin K, Talpaz M, Sledge Jr. GW, Holmgren E, Benjamin R et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
19. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012; 40: 1321-1330
20. Lee SH. Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34: 1223-1226
21. Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011; 13: 97-102
22. Lee S, Chung J, Ha IS, Yi K, Lee JE, Kang HG et al. Hydrogen peroxide increases human leukocyte adhesion to porcine aortic endothelial cells via NFkappaBdependent up-regulation of VCAM-1. Int Immunol 2007; 19: 1349-1359
23. Sambrook J, Russell DW. Molecular cloning: A laboratory manual. 3rd ed. (Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001
24. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies - application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 28-39
25. Van Meter KE, Stuart MK. A monoclonal antibody that inhibits translation in Sf21 cell lysates is specific for glyceraldehyde-3-phosphate dehydrogenase. Arch Insect Biochem Physiol 2008; 69: 107-117
26. Barbas CF. Phage display: A laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001
27. Vestweber D. Lymphocyte trafficking through blood and lymphatic vessels: More than just selectins, chemokines and integrins. Eur J Immunol 2003; 33: 1361-1364
28. Alon R, Feigelson S. From rolling to arrest on blood vessels: Leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002; 14: 93-104
29. Kim HY, Tsai S, Lo SC, Wear DJ, Izadjoo MJ. Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system. PLoS One 2011; 6: e19867